S 11566 | CAS#121454-18-0 | D3 receptor antagonist

MedKoo Cat#: 461605 | Name: S 11566

Description:

WARNING: This product is for research use only, not for human or veterinary use.

S 11566 is a selective dopamine D3 receptor antagonist.

Chemical Structure

S 11566

CAS#121454-18-0

Theoretical Analysis

MedKoo Cat#: 461605

Name: S 11566

CAS#: 121454-18-0

Chemical Formula: C18H27NO

Exact Mass: 273.2093

Molecular Weight: 273.42

Elemental Analysis: C, 79.07; H, 9.95; N, 5.12; O, 5.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

S 11566; S-11566; S11566;

IUPAC/Chemical Name

N,N-dipropyl-2,3,5,6,7,8-hexahydronaphtho[2,3-b]furan-7-amine

InChi Key

IJICKINLCUKIHY-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H27NO/c1-3-8-19(9-4-2)17-6-5-14-11-15-7-10-20-18(15)13-16(14)12-17/h11,13,17H,3-10,12H2,1-2H3

SMILES Code

CCCN(CCC)C1CCC2=C(C=C3OCCC3=C2)C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 273.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Millan MJ, Gressier H, Brocco M. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol. 1997 Mar 5;321(3):R7-9. PubMed PMID: 9085054. 2: Millan MJ, Audinot V, Melon C, Newman-Tancredi A. Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. Eur J Pharmacol. 1995 Jul 4;280(2):225-9. PubMed PMID: 7589191. 3: Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther. 1995 Nov;275(2):885-98. PubMed PMID: 7473180. 4: Rivet JM, Audinot V, Gobert A, Peglion JL, Millan MJ. Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol. 1994 Nov 24;265(3):175-7. PubMed PMID: 7875234. 5: Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther. 1995 Nov;275(2):899-913. PubMed PMID: 7473181. 6: Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther. 1998 Oct;287(1):187-97. PubMed PMID: 9765337. 7: Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL. S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol. 1994 Aug 1;260(2-3):R3-5. PubMed PMID: 7988633. 8: Newman-Tancredi A, Audinot V, Jacques V, Peglion JL, Millan MJ. [3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors. Neuropharmacology. 1995 Dec;34(12):1693-6. PubMed PMID: 8788967. 9: Yoshikawa T, Yoshida N. The possible involvement of dopamine D3 receptors in the regulation of gastric emptying in rats. Life Sci. 2010 Nov 20;87(19-22):638-42. doi: 10.1016/j.lfs.2010.09.027. Epub 2010 Oct 1. PubMed PMID: 20888837. 10: Gobert A, Lejeune F, Rivet JM, Cistarelli L, Millan MJ. Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem. 1996 May;66(5):2209-12. PubMed PMID: 8780056. 11: Perachon S, Betancur C, Pilon C, Rostène W, Schwartz JC, Sokoloff P. Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport. 2000 Jan 17;11(1):221-5. PubMed PMID: 10683862. 12: Lejeune F, Millan MJ. Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol. 1995 Mar 14;275(3):R7-9. PubMed PMID: 7768288. 13: Morris BJ, Newman-Tancredi A, Audinot V, Simpson CS, Millan MJ. Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons. J Neurosci Res. 2000 Mar 15;59(6):740-9. PubMed PMID: 10700011. 14: Millan MJ, Girardon S, Monneyron S, Dekeyne A. Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. PubMed PMID: 10728880.